title: Esophageal actinomycosis after allogeneic peripheral blood stem cell transplantation for extranodal natural killer/T cell lymphoma, nasal type.
abstract: We report a 19-year-old man with extranodal natural killer (NK)/T cell lymphoma, nasal type treated by allogeneic peripheral blood stem cell transplantation (allo-PBSCT). His lymphoma was chemoresistant, and disseminated during local radiotherapy. The patient received allo-PBSCT from his HLA-1 locus mismatched sister using busulfan (BU), cyclophosphamide (CY) and VP-16 as the conditioning regimen. His course was complicated by esophageal actinomycosis 9 months after transplantation, which resulted in the rupture of the right common carotid artery. These observations suggest that actinomycosis should be monitored carefully after transplantation in patients who have received local radiation therapy before the procedure.
authors.affiliation: Department of Laboratory Medicine, Osaka City General Hospital, Miyakojimahondori, Miyakojima-ku, Osaka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Yagi
authors.forename: H
authors.initials: H
authors.lastname: Fujino
authors.forename: M
authors.initials: M
authors.lastname: Hirai
authors.forename: T
authors.initials: T
authors.lastname: Inoue
authors.forename: M
authors.initials: M
authors.lastname: Sako
authors.forename: H
authors.initials: H
authors.lastname: Teshima
authors.forename: S
authors.initials: S
authors.lastname: Fujii
authors.forename: M
authors.initials: M
authors.lastname: Hino
mesh_terms: D000196:Actinomycosis / Q000209:etiology / Q000473:pathology*; D000328:Adult; D002066:Busulfan / Q000494:pharmacology; D003520:Cyclophosphamide / Q000494:pharmacology; D004935:Esophageal Diseases / Q000473:pathology*; D005047:Etoposide / Q000494:pharmacology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000166:cytology; D016399:Lymphoma, T-Cell / Q000628:therapy*; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects*; D013997:Time Factors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous / Q000009:adverse effects* / Q000473:pathology
chemical_list: D007166:Immunosuppressive Agents; D005047:Etoposide; D003520:Cyclophosphamide; D002066:Busulfan